Royal UNIBREW A/S
COMPANY ANNOUNCEMENT NO 12/2021 – 15 MARCH 2021
On 3 March 2021, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 9/2021 of 3 March 2021. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the Market Abuse Regulation - MAR) and the resulting delegated legislation. The share buy-back program is expected to be realized in the period from 4 March 2021 to 30 June 2021. The total share buy-back in the period will not exceed a market price of DKK 250 million.
The following transactions have been made under the program:
Number of Shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 5,243 | 629.80 | 3,302,049.17 |
8 March 2021 | 9,000 | 648.44 | 5,835,993.30 |
9 March 2021 | 3,154 | 651.93 | 2,056,189.43 |
10 March 2021 | 2,162 | 674.66 | 1,458,616.00 |
11 March 2021 | 3,539 | 667.42 | 2,361,993.72 |
12 March 2021 | 3,874 | 664.89 | 2,575,776.11 |
Accumulated under the program | 26,972 | 652.18 | 17,590,617.73 |
With the transactions stated above Royal Unibrew owns a total of 794,412 shares, corresponding to 1.6% of the share capital. The total amount of shares in the company is 49,350,000, including treasury shares.
For further information on this Announcement:
CFO Lars Vestergaard, tel (+45) 30 93 18 08
www.royalunibrew.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Ingredion Incorporated16.9.2025 12:05:00 CEST | Press release
Ingredion to Webcast Investor Day on September 17
Novo Nordisk A/S16.9.2025 12:00:32 CEST | Press release
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme
SEON16.9.2025 12:00:00 CEST | Press release
SEON Closes $80 Million Series C Led by Sixth Street Growth to Scale Command Center for Fraud Prevention and AML Compliance as Digital Fraud Set to Exceed Billions Annually
Quest Software Inc.16.9.2025 12:00:00 CEST | Press release
Quest Software Announces New Company Strategy and Unified Data Management Platform for AI Success
Pandora A/S16.9.2025 11:07:31 CEST | Press release
Transactions in connection with share buyback programme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom